US 12,234,263 B2
Influenza vaccines
Arthur Young, Cypress, CA (US); Ren Sun, Los Angeles, CA (US); and Nicholas C. Wu, Los Angeles, CA (US)
Assigned to InvVax, Inc., Pasadena, CA (US); and The Regents of the University of California, Oakland, CA (US)
Filed by InvVax, Inc., Pasadena, CA (US); and The Regents of the University of California, Oakland, CA (US)
Filed on Jun. 30, 2023, as Appl. No. 18/344,909.
Application 18/344,909 is a continuation of application No. 17/375,797, filed on Jul. 14, 2021, granted, now 11,739,127.
Application 17/375,797 is a continuation of application No. 15/857,436, filed on Dec. 28, 2017, granted, now 11,111,277, issued on Sep. 7, 2021.
Claims priority of provisional application 62/550,167, filed on Aug. 25, 2017.
Claims priority of provisional application 62/439,865, filed on Dec. 28, 2016.
Prior Publication US 2023/0416311 A1, Dec. 28, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/86 (2006.01); A61K 39/12 (2006.01); A61K 39/145 (2006.01); A61P 31/16 (2006.01); C07K 14/005 (2006.01); C07K 14/075 (2006.01); C07K 14/11 (2006.01); A61K 39/00 (2006.01)
CPC C07K 14/11 (2013.01) [A61K 39/12 (2013.01); A61K 39/145 (2013.01); A61P 31/16 (2018.01); C07K 14/005 (2013.01); C07K 14/075 (2013.01); C12N 15/86 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/5258 (2013.01); A61K 2039/53 (2013.01); A61K 2039/543 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55555 (2013.01); A61K 2039/57 (2013.01); A61K 2039/6018 (2013.01); A61K 2039/70 (2013.01); C12N 2710/10343 (2013.01); C12N 2760/16134 (2013.01); C12N 2760/16234 (2013.01); C12N 2760/16334 (2013.01)] 20 Claims
 
1. A non-naturally-occurring polypeptide comprising at least a first epitope, a second epitope, and a third epitope, wherein the first epitope, the second epitope, and the third epitope differ from each other;
wherein the first epitope, the second epitope, and the third epitope are selected from the group consisting of SEQ ID NOs: 40, 58, 61, 43, 51, 93, 22, 49, 82, 88, 34, and a variant of SEQ ID NO: 88 that lacks the N-terminus V residue.